Objectives-The predictive value of animal and in vitro systems for drug development is limited, particularly for nonhuman primate studies as it is difficult to deduce the drug mechanism of action. We describe the development of an in vitro cynomolgus macaque vascular system that reflects the in vivo biology of healthy, atheroprone, or advanced inflammatory cardiovascular disease conditions. Approach and Results-We compare the responses of the in vitro human and cynomolgus vascular systems to 4 statins.
D rug discovery involves initial target identification and validation for a disease with subsequent development of compounds to act on that target for disease intervention. Lead compounds are then optimized for safety and efficacy and undergo preclinical testing before entering clinical phase trials. Preclinical testing is important in predicting drug safety and efficacy in humans by performing validation trials in nonhuman animal models. These trials are costly, time consuming, and often involve multiple animal species, including nonhuman primates. Nonhuman primates may predict human drug response; however, their use is expensive and difficult. Moreover, when a negative result occurs, further experimentation to unmask the mechanism is considered unethical and is not warranted in nonhuman primates. Thus, the development of promising drugs is often prematurely terminated. The establishment of physiologically relevant in vitro animal model systems that provide strong predictive value is crucial for optimizing the drug development process. Here, we describe the development of an in vitro cynomolgus vascular surrogate system to aid in nonhuman primate studies.
The development of the cynomolgus vascular system was modeled after our well-characterized human vascular tissue system. 1 This system mimics the in vivo endothelial and smooth muscle architecture, biology and physiology of the blood vessel wall, and is highly responsive to changes in hemodynamics, inflammatory milieu, and drug treatments. The vascular model has been configured to reflect an advanced inflammatory state characteristic of patients with atherosclerosis. [1] [2] [3] [4] [5] [6] Cynomolgus macaques (Macaca fascicularis) are the most widely used nonhuman primates for atherosclerosis. 7 Cynomolgus macaques are highly responsive to atherogenic diets, and the atherogenic response is influenced by lipoprotein diet composition. Atherogenic diet-fed cynomolgus macaques develop coronary artery lesions, raised plasma cholesterol levels, and lesions of similar composition to humans. Atherosclerosis development in cynomolgus macaques is highly influenced by genetic predisposition, confounding diseases (such as diabetes mellitus), exercise, sex (increased susceptibility in men), and behavioral and psychosocial factors. October 2015 All of these characteristics are similar to the human atherosclerosis disease, and thus, they make cynomolgus macaques a good nonhuman primate model for atherosclerosis. 7, 8 In this study, a cynomolgus vascular system was developed using primary endothelial cells (ECs), smooth muscle cells (SMCs), and hemodynamics derived in vivo from cynomolgus arteries. The system was validated against inflammatory risk factor response, including a comparison between human-and cynomolgus-derived oxidized low-density lipoproteins (LDLs), and exposure to several statins. A comparative analysis between the cynomolgus and human vascular tissue systems was conducted to determine the cross-species translational capabilities of these models, which is an important component in the transition from preclinical to human clinical studies.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Development of an In Vitro Cynomolgus Vascular Surrogate System
The human vascular surrogate system applies human-derived blood shear stress patterns to a transwell vascular coculture of ECs and SMCs ( Figure 1A ). Atherosclerotic lesions develop primarily at arterial sites of disturbed blood flow characterized by low time-averaged and oscillatory wall shear stress, often in bifurcated areas or regions of high curvature. Blood velocity profiles were previously obtained by magnetic resonance imaging from the human common carotid artery and the internal carotid sinus regions 4 ( Figure 1B ). These measurements correlate with vascular regions that exhibit atheroprotective and atheroprone phenotypes, respectively. 3 The cynomolgus vascular surrogate system applies the same correspondence of hemodynamic principles. Cynomolgus blood velocity profiles were acquired by ultrasound and wall shear stress values determined from the corresponding cynomolgus common carotid artery and the carotid bulb regions ( Figure 1B ).
Compared with human hemodynamic waveforms, there are several distinct differences in the profile patterns between cynomolgus and humans. In particular, the cynomolgus carotid bulb waveform exhibits reversal in blood flow with diminished pulsatile flow, whereas the human internal carotid sinus region mostly loses pulsatile flow ( Figure 1B ). The cynomolgus shear stress magnitude is much greater than the shear stress in humans (Table 1) . Nevertheless, the cynomolgus common carotid and carotid bulb waveforms are used to mimic atheroprotective and atheroprone arterial regions in the cynomolgus macaque. 7 The wall shear stress profiles are then applied to the respective cynomolgus and human vascular systems by way of a cone-and-plate viscometer that is incorporated into the EC and SMC transwell coculture setup ( Figure 1A ). Representative images of cynomolgus ECs and SMCs exposed to the cynomolgus atheroprotective waveform are shown ( Figure 1A ).
Initial characterization of the cynomolgus vascular surrogate system involved comparison with known hemodynamic effects imparted on human vascular cells. The cynomolgus and human vascular systems were exposed to atheroprotective and atheroprone hemodynamics for 48 hours, and gene expression patterns of the cynomolgus ECs and SMCs were determined by RNA sequencing. Initially, a panel of EC shear stress response genes was assessed in the presence or absence of hemodynamic flow, including genes important in promoting vascular endothelial health (kruppel-like factor 2 [KLF2], kruppel-like factor 4 [KLF4], endothelial nitric oxide synthase 3 [eNOS3], and heme oxygenase 1 [HMOX1]). eNOS is a potent vasodilator with strong inhibitory effects of platelet and monocyte activation and sustains vascular health by promoting antithrombotic and anti-inflammatory effects. The KLF2 and KLF4 transcription factors can positively regulate eNOS expression. 9,10 HMOX1 is an oxidative stress response gene that has anti-inflammatory and vasoregulatory effects. The shear stress response is also characterized by downregulation of inflammatory and vasoconstrictive markers, such as C-X-C chemokine receptor type 4, chemokine ligand 2, angiopoietin 2, and endothelin 1 (EDN1). The analysis of shear stress activation of these genes demonstrates that the cynomolgus endothelial layer appropriately regulates these classical shear stress response genes when compared with samples not exposed to hemodynamics. An even greater effect was observed with the atheroprotective common carotid waveform ( Figure 1C ). Furthermore, we compared the fold changes in gene expression in ECs from our cynomolgus versus human vascular systems that were exposed to atherogenic hemodynamics from the common carotid and carotid bulb regions. We sought to determine similarities in gene expression fold change and directionality between the 2 systems when responding to changes in hemodynamics. To compare the effects of 2 different treatments, individual gene fold changes were plotted on the x and y axes. Overall, the expression of a large number of endothelial genes changed in the same direction when comparing the responses to hemodynamics of the cynomolgus and human vascular systems ( Figure 1D , purple dots). However, in a relatively small subset of genes, the fold changes in expression were in opposite directions when comparing the 2 species ( Figure 1D , green dots). Most of the endothelial genes changed in the same direction (response similarity index [RSI]>0) in response to atherogenic hemodynamics when comparing the 2 species; in ECs, the ratio of genes with an RSI of >0.2 to genes with an RSI of <−0. 
Characterization of Cynomolgus-and Human-Derived Oxidized LDL
ECs exposed to atheroprone hemodynamics promote inflammation, monocyte transmigration and differentiation into macrophages, and subsequent atherosclerosis. 11 Key components of the inflammatory milieu that predispose this region to atherosclerosis are tumor necrosis factor-α (TNF-α) and oxidized LDL (oxLDL). To mimic an advanced inflammatory state of atherogenesis, TNF-α and oxLDL were added to cells exposed to atheroprone hemodynamics. Because of the challenge of accessing large quantities of cynomolgus LDL, we tested whether cynomolgus-derived oxLDL or human-derived oxLDL would have a similar effect. Species-specific effects of oxLDL on the cynomolgus system were compared by transcriptomic analysis of RNA sequencing data and Western blot analysis.
Comparison of oxLDL-versus native LDL-mediated effects reveals that the overwhelming majority of genes in ECs and SMCs exhibit highly similar fold change and expression directionality between cynomolgus-and humanderived oxLDL (Figure 2A) ; in ECs and SMCs, the ratio of genes with an RSI of >0.2 to genes with an RSI of <−0.2 was 91:1 and 49:1, respectively ( Figure II in the online-only Data Supplement). The analysis of key vascular health genes reveals that both species of oxLDL reduced the expression of Figure 1 . Development of a cynomolgus vascular surrogate system. A, Species-specific wall shear stress profiles were applied to the cynomolgus or human vascular surrogate systems using a cone-and-plate viscometer incorporated into a transwell coculture model of endothelial cells (ECs; green) or smooth muscle cells (SMCs; red). Rotation of the cone (orange triangle) imparts downward directional shear stress onto the ECs. Media is continually perfused to recapitulate interstitial flow, as indicated by the inflow and outflow ports. Representative photomicrographs of cynomolgus ECs and SMCs exposed to cynomolgus hemodynamics from the common carotid arterial region are shown (green, phalloidin; red, smooth muscle α-actin; scale bar, 100 μm). B, Blood velocity profiles were acquired by ultrasound from the carotid bulb and common carotid artery from a cynomolgus macaque. Ultrasound measurements were used to calculate wall shear stress values. Human waveforms from the same regions were acquired by magnetic resonance imaging. C, Cynomolgus vascular surrogate system was exposed to hemodynamics from the carotid bulb and common carotid arterial regions for 48 hours, and ECs and SMCs were processed for RNA sequencing. ECs appropriately modulated classic shear stress responsive genes when compared with control samples not exposed to hemodynamics. Gene expression is represented on the heatmap as log 2 fold (red, upregulation; blue, downregulation). D, Scatterplot representation of differentially expressed genes (DEGs) in ECs comparing carotid bulb versus common carotid hemodynamics in both the cynomolgus and human vascular systems. Each point represents log 2 fold change of a DEG for cynomolgus and human. A DEG with the same directionality in fold change for both species is represented in purple, whereas a DEG exhibiting opposite directionality is represented in green. The color intensity increases with statistical significance. The response similarity index (RSI) value is a single numeric value that incorporates the fold change and significance for each DEG in both species. endothelial NOS3 and smooth muscle ACTA2 (smooth muscle alpha-actin 2 gene) and KLF2 ( Figure 2B ). Cynomolgus-and human-derived oxLDL also upregulate oxidative stressreducing genes (HMOX1 and superoxide dismutase 2), cell adhesion molecules (CAMs; E-selectin, intercellular adhesion molecule 1, and vascular adhesion molecule 1 [VCAM1]), and proinflammatory markers (interleukin [IL]-6, IL-8, chemokine ligand 2, and nuclear factor of κ light polypeptide gene enhancer in B-cells 1) in ECs and SMCs ( Figure 2B ). VCAM1 is likely upregulated by TNF-α and oxLDL in the intima of developing atherosclerotic plaques. 12 ACTA2 encodes smooth muscle α-actin and is a marker of the smooth muscle contractile phenotype characterized by a quiescent, differentiated state. Downregulation of ACTA2 expression suggests that SMCs have lost their contractile phenotype and may have acquired a more proliferative, migratory phenotype. 13 The cynomolgus-derived oxLDL-mediated increase in VCAM1 and decrease in ACTA2 gene expression were confirmed at the protein level by Western blot ( Figure 2C ).
Statin Treatment of Cynomolgus and Human Vascular Systems
Next, we exposed the cynomolgus vascular system to a wellcharacterized drug class and compared its response to the human system. Statins are a well-studied and ubiquitous class of drugs with proven efficacy for lipid-lowering and pleiotropic anti-inflammatory vascular effects. The cynomolgus and human vascular systems exposed to advanced inflammatory conditions were treated with 4 statins or the vehicle control. Rosuvastatin, atorvastatin, simvastatin, and cerivastatin were The cyno vascular surrogate system was exposed to atheroprone carotid bulb hemodynamics for 18 hours and then to baseline atheroprone or advanced inflammatory conditions for an additional 30 hours. The baseline atheroprone condition is achieved by adding cyno-or human-derived native LDL (nLDL; 10 μg/mL), whereas the advanced inflammatory condition is achieved by adding tumor necrosis factor-α (TNF-α; 0.05 ng/mL) and cyno-or human-derived oxLDL (10 μg/mL). A, Scatterplot representation of cyno endothelial cell (EC) and smooth muscle cell (SMC) differentially expressed genes (DEGs) comparing oxLDL+TNF-α versus nLDL response when LDL is of cyno or human origin. Each point represents log 2 fold change of a DEG for cyno and human. A DEG exhibiting similar directionality in fold change for both species is represented in purple, whereas a DEG exhibiting opposite directionality is represented in green. The color intensity increases with statistical significance. The response similarity index (RSI) is a single numeric value that incorporates the fold change and significance for each DEG in both species. The human-and cyno-derived oxLDL induced strikingly similar changes in gene expression. B and C, Cells were processed for RNA deep sequencing and Western blot analyses and key vascular health gene and protein expression were evaluated. RNA deep sequencing compares cells exposed to both cyno-and human-derived nLDL and oxLDL, whereas Western blot data compares cells exposed only to cyno-derived nLDL and oxLDL. Gene expression is represented on the heatmap as log 2 fold (red, upregulation; blue, downregulation). Representative Western blots with quantitative Student t test analyses are presented. SMAA indicates smooth muscle α-actin; and VCAM, vascular adhesion molecule.
Table 1. Blood Velocity Profiles Characterized From the Common Carotid and Carotid Bulb/Carotid Sinus Arterial Regions of the Cynomolgus Macaques and Humans
Cynomolgus Human administered at the highest Food and Drug Administrationapproved human C max concentration ( Table 2) . Global gene expression responses in statin-treated cynomolgus cells reveal that statins have the greatest response in ECs as observed by greater differentially expressed gene counts in ECs versus SMCs ( Figure 3 ). Furthermore, cerivastatin exerted the maximal effect in both ECs and SMCs, with a greater response in SMCs (Figure 3 ). However, the rosuvastatin response was minimal ( Figure 3) . Statins have been reported to exert beneficial pleiotropic effects on the vascular wall independent of cholesterol reduction. In the cynomolgus and human endothelium, statin treatment, except rosuvastatin, was found to increase NOS3, KLF2, and KLF4 and reduce cytokine IL-1B, IL-1A, IL-6, IL-8, chemokine (C-X-C motif) ligand 12, and EDN1 gene expression, supporting a healthier, less inflamed phenotype . Each DEG is plotted by its fold change versus its chance of being a DEG. The false discovery rate (FDR) at various cutoffs is indicated. DEGs that fall above the FDR 10% cutoff are considered statistically significant. October 2015 ( Figure 4A ). Gene expression for CAMs, E-selectin, VCAM1, and intercellular adhesion molecule 1, was not reduced, and in fact, it was upregulated by statins, except for simvastatin and cerivastatin in human ECs and rosuvastatin ( Figure 4A ). CAM P-selectin was also upregulated by all conditions, except rosuvastatin ( Figure 4A ). All statins, except rosuvastatin, also exerted some beneficial effects on the cynomolgus and human smooth muscle layer in the vascular systems, with a greater response in human ( Figure 4B ). EDN1 was downregulated, and it mediates smooth muscle vasoconstriction ( Figure 4B) . Furthermore, key genes of the coagulation pathway are differentially regulated by statins to promote an antithrombotic effect. Thrombomodulin is upregulated and inhibits thrombin, a major activator of coagulation; tissue-type plasminogen activator is upregulated and promotes fibrinolysis, and thus, it decreases thrombus formation; endothelial plasminogen activator inhibitor is downregulated and is an inhibitor of tissue-type plasminogen activator activity; coagulation factor 3 is downregulated and is a procoagulation factor ( Figure 4B ). Despite these beneficial effects, statin treatment reduced the gene expression of key markers of smooth muscle contractility, including ACTA2, caldesmon 1, myosin light chain kinase, transgelin, and myocardin ( Figure 4B ). Increased KLF4 expression in the SMCs can also promote loss of the differentiated SMC contractile phenotype ( Figure 4B ). Aside from anticipated vascular-specific effects imparted by statins, a pathway-weighting approach identified several biological themes that are not specific to the vasculature. These include cell cycle regulation, ethanol degradation, and glycogen metabolism. Cynomolgus-and human-derived oxLDL induced a global downregulation of many cell cycle regulatory genes, including cyclins and minichromosome maintenance proteins, whereas cyclin-dependent kinase inhibitors were upregulated ( Figure 5A ). This effect was further enhanced by statin treatment, except for rosuvastatin ( Figure 5A ). Global downregulation of cell cycle regulatory proteins was more pronounced in ECs ( Figure 5A ). Proliferating cell nuclear antigen protein was also downregulated in cynomolgus ECs and SMCs by oxLDL, consistent with reduced cell cycle gene regulation by oxLDL ( Figure 5B ). No significant changes were observed for growth arrest and DNA damage 45 protein levels by oxLDL ( Figure 5B) ; growth arrest and DNA damage 45 is induced by DNA damage to activate the G2/M checkpoint and subsequent growth suppression. Furthermore, ethanol metabolism generates many toxic acetaldehyde byproducts that must be further metabolized by acetaldehyde dehydrogenases to prevent their accumulation. Acetaldehyde dehydrogenases belong to the aldehyde dehydrogenase (ALDH) family and include ALDH1A1, ALDH2, and ALDH1B1. 14 Although ALDH2 is the main enzyme that metabolizes acetaldehydes, ALDH1A1 and ALDH1B1 can also act on these byproducts. We observed that oxLDL and statins downregulate ALDH1A1 and ALD1B1 under many conditions, which may promote acetaldehyde accumulation ( Figure 5C ). Finally, many genes important in glycogen regulation and metabolism were also found to be downregulated by statin treatment in cynomolgus and human vascular cells, with the exception of rosuvastatin that elicited no changes and cerivastatin that upregulated phosphorylase, glycogen, brain, phosphoglycerate mutase 2, and phosphoenolpyruvate carboxykinase 2 in human SMCs and phosphoenolpyruvate carboxykinase 2 in cynomolgus SMCs ( Figure 6 ). Perturbation of gene expression of this pathway will impair glycogen regulation and may lead to inefficient glucose utilization and storage.
Discussion
We describe the successful development of a cynomolgus vascular surrogate system that recapitulates expected biology observed in the vascular wall. The cynomolgus vascular system responds to natural arterial shear stress patterns from the common carotid and carotid bulb regions in a manner that reflects the atheroprotective and atheroprone conditions, respectively. Precise regional shear stress activates classical shear stress atheroprotective responsive genes in the vascular endothelium, including NOS3, KLF2, KLF4, and HMOX1. 9, [15] [16] [17] These hemodynamics also reduce the expression of proinflammatory cytokines, vasoregulatory proteins, and genes that disrupt EC barriers, such as chemokine ligand 2, EDN1, C-X-C chemokine receptor type 4, and angiopoietin 2. [18] [19] [20] Thus, the cynomolgus vascular endothelium, when in direct contact with local hemodynamics, responds in a way that closely correlates with the human vascular system.
Comparison of cynomolgus-versus human-derived oxLDL is important in assessing differences in species-specific effects of LDL. Similar to humans, the cynomolgus macaque is highly responsive to elevated dietary cholesterol levels, 21, 22 leading to increased serum lipids and altered lipid composition. Compared with other nonhuman primates, cynomolgus LDL exhibits increased atherogenic potential because of its larger, polydisperse LDL and increased apolipoprotein E fraction. 21 This larger size will increase the amount of cholesterol ester per LDL particle delivered to cells, increasing the rate of cholesterol ester accumulation and plaque development. The metabolic heterogeneity of responses induced by cynomolgus-versus human-derived oxLDL can in large part be predicted by the heterogeneous composition of elevated LDL. Assessing the differences in oxLDL composition will be useful in identifying metabolic and genetic predictors for responses to dietary cholesterol and how responses between the systems can be compared. Our studies reveal that cynomolgus-and human-derived oxLDL elicit nearly identical responses in the cynomolgus vascular wall under advanced inflammatory conditions, as measured by high overlap of differentially expressed gene response. These similarities suggest that human LDL may be substituted for studies when cynomolgus LDL is scarce.
Statin-mediated responses in the cynomolgus vascular system were compared with our human surrogate system. Cerivastatin elicited the most robust response, whereas rosuvastatin had little-to-no effect (Figure 3) . Cerivastatin exhibits the greatest bioavailability at 60% compared with 14% and <5% for atorvastatin and simvastatin, respectively. Cerivastatin, along with atorvastatin and simvastatin, is a lipophilic compound that can passively diffuse through the cell membrane, whereas rosuvastatin is hydrophilic and requires active transport. The ABC and SLC gene family transporters are responsible for carrier-mediated uptake of statins and are primarily hepatic-specific markers. 23, 24 Thus, decreased expression of these transporters in the vascular wall will blunt rosuvastatin-mediated effects, supporting the idea the hydrophilic statins are less effective intracellular agents. The minimal rosuvastatin-mediated response is also consistent with reported lack of lipid-lowering effects by rosuvastatin in cynomolgus macaques. 25 Thus, the observed statin response is consistent with the physiochemical properties of each statin and was consistent between cynomolgus and humans.
Statin treatment, particularly with the lipophilic statins, was able to reverse many of the detrimental effects induced by advanced inflammatory conditions. Endothelial proinflammatory cytokines IL-1A, IL-6, and IL-8 were downregulated by Figure 5 . Statin regulation of genes important for cell cycle and ethanol degradation. The cynomolgus (Cyno) and human vascular surrogate systems were exposed to baseline atheroprone (10 μg/mL of Cyno-derived native low-density lipoprotein [nLDL] or 50 μg/mL of human-derived nLDL, respectively) or advanced inflammatory conditions (10 μg/mL of Cyno-derived oxidized LDL [oxLDL]+0.05 ng/mL of tumor necrosis factor-α [TNF-α] or 50 μg/mL of human-derived oxLDL+0.05 ng/mL of TNF-α, respectively) with either vehicle control or statin treatment. In addition, Cyno cells were exposed to healthy common carotid hemodynamics with Cyno-derived nLDL. A, Analysis of gene expression reveals that cell cycle genes are significantly reduced by statin treatment in both the endothelial cell (EC) layer and the smooth muscle cell (SMC) layer. B, Western blot analysis for proliferating cell nuclear antigen (PCNA) and growth arrest and DNA damage 45 (GADD45) protein expression was performed to assess regulation of cell cycle protein markers from Cyno cells. Representative Western blots with quantitative Student t test analysis are presented. C, Gene expression of the ethanol degradation pathway is regulated by statin treatment in both cell types. Gene expression is represented on the heatmaps as log 2 fold (red, upregulation; blue, downregulation). statins in human ECs. This is consistent with reported decreases of serum IL-6, IL-8, and CXCL12 in human patients. 26, 27 In addition, key genes (NOS3, KLF2, and KLF4) for maintaining EC health were upregulated by statins, whereas EDN1 was downregulated. Statins improve arterial dilatory function in cynomolgus macaques and humans, in part, through regulating eNOS, KLF2, and KLF4 expression. [28] [29] [30] Finally, statins promote antithrombotic effects, 28 manifesting in this study as decreased prothrombotic (coagulation factor 3 and endothelial plasminogen activator inhibitor) and increased antithrombotic (thrombomodulin and tissue-type plasminogen activator) gene expression. The beneficial effects exerted by statin treatment are thought to be independent of lipid-lowering effects given that these changes are observed acutely before lipid changes. 28 Figure 6 . Statins may impair glycogen metabolism/glycolysis by downregulating genes of this pathway. The cynomolgus (Cyno) and human vascular surrogate systems were exposed to baseline atheroprone (10 μg/mL of Cyno-derived native low-density lipoprotein [nLDL] or 50 μg/mL of human-derived nLDL, respectively) or advanced inflammatory conditions (10 μg/mL of Cyno-derived oxidized LDL [oxLDL]+0.05 ng/mL of tumor necrosis factor-α [TNF-α] or 50 μg/mL of human-derived oxLDL+0.05 ng/mL of TNF-α, respectively) with either vehicle control or statin treatment. Statin-mediated regulation of gene expression of key genes of the glycogen metabolism/ glycolysis pathway is represented in the heatmap. Gene expression is represented on the heatmaps as log 2 fold (red, upregulation; blue, downregulation). A schematic of the pathway and key genes for glycogen metabolism, glycolysis, and gluconeogenesis is represented. EC indicates endothelial cell; and SMC, smooth muscle cell. As a consequence, independent of lipid lowering, statins may improve (1) endothelial function via increased nitric oxide production (due to increased NOS3), (2) anti-inflammatory effects due to reduction of acute phase proteins, (3) antioxidant effects due to increased scavenging of superoxide and inhibition of superoxide generators, (4) antithrombotic effects that promote fibrinolysis and decrease platelet aggregation, and (5) stabilization of atherosclerotic plaque. Unexpectedly, gene expression for CAMs, E-selectin, VCAM1, and intercellular adhesion molecule 1, was not reduced and in fact was upregulated by statin treatment under most conditions. This effect is consistent with the lack of in vivo statin-mediated reduction on circulating E-selectin, VCAM1, and intercellular adhesion molecule 1 expression in patients with hypercholesterolemia. 31, 32 Although the reason for this lack of CAM reduction is not clear, it may be a function of persistent oxLDL in the circulating serum that may directly act to upregulate CAMs. oxLDL can upregulate CAM expression in a TNF-α-dependent manner. 33, 34 In fact, TNF-α genes are upregulated under conditions with elevated CAM expression despite decreased expression of cytokine expression (data not shown). However, maintained lipid reduction may lead to reduced CAM expression. Furthermore, markers of SMC contractility were decreased. Although the SMC contractile phenotype is important in maintaining cell quiescence, statins are known to decrease these markers, such as myocardin, a global transcriptional regulator of SMC markers, and prevent vascular contraction. 35, 36 Coupled with statin-mediated NOS3 increase, this can contribute to reported statin-mediated vasodilatory effects.
Table 3. Summary of Gene Mutations That Lead to Muscle Pathologies and the Observed Statin-Induced Gene Expression of Those Genes in the Cynomolgus and Human Vascular Surrogate Systems
We also demonstrated that the cynomolgus vascular surrogate system responds to statin treatment consistent with positive statin-mediated pleiotropic effects observed in cynomolgus in vivo, as well as human patients, and in the human vascular system. Clinical evidence suggests that statin treatment is associated with antiproliferative and antimetastatic properties. 37 Statin inhibition of hydroxymethylglutaryl CoA reductase results in inhibition of the cholesterol biosynthetic pathway. Mevalonate is a precursor of cholesterol and other lipid products, many of which regulate cell cycle, such as dolichol, geranylpyrophosphate, and farnesylpyrophosphate. Dolichol stimulates DNA synthesis, whereas geranylpyrophosphate and farnesylpyrophosphate cause isoprenylation of intracellular Ras and Rho G-proteins, important signaling molecules that influence gene transcription of cell cycle regulatory proteins. In addition to lipid-lowering effects mediating reduced cell proliferation, we observed that cyclins and minichromosome maintenance proteins are downregulated, whereas cyclin-dependent kinase inhibitors are upregulated. In fact, consistent with reports demonstrating that cell cycle kinase inhibitors p21 and p27 are stabilized, thereby arresting cells in the G 1 phase of the cell cycle, 37 we observed that the genes cyclin-dependent kinase inhibitor 1A and cyclindependent kinase inhibitor 1B for these kinase inhibitors, respectively, are upregulated. Interestingly, statins alone may not be effective anticancer agents; when combined with other cytotoxic agents, data suggest an improvement in chemotherapeutic effects. 37 The cynomolgus and human vascular systems provide a useful platform in which dual therapy regimens can be easily tested for safety and efficacy while elucidating the drug mechanism of action.
The cynomolgus and human vascular systems were invaluable in providing mechanistic insight into the pleiotropic vascular effects independent of cholesterol lowering by statins. Computational analysis of the differentially expressed genes revealed multiple common biological pathways regulated by each statin treatment that yielded clues to mechanisms for observed off-target effects. Cerivastatin was withdrawn from the market because of high reported incidences of rhabdomyolysis, a condition characterized by breakdown of muscle tissue and release of myoglobin into blood. Myoglobinuria can cause renal damage and is potentially fatal. Thus, patients taking statins are warned to immediately discontinue use if any symptom of muscle pain or weakness is experienced. Consistent with this off-target effect, we observed that many genes regulating glycogen metabolism were downregulated by all statins, except rosuvastatin, in cynomolgus and human cells. Carbohydrate utilization from intramuscular glycogen stores via glycogenolysis is necessary to provide the necessary energy for working muscles. If enzymes regulating this process are low or absent, myopathy and eventual rhabdomyolysis can result. Altered regulation of many genes regulating glycogen metabolism is associated with symptoms of myopathy (Table 3 ). We observed that statin treatment in the cynomolgus and human vascular systems alters the expression level of these genes in a manner that is consistent with myopathy (Table 3 ; Figure 6 ). In particular, cerivastatin exhibits the most robust response of genes implicated in myopathies, consistent with its clinical incidence of rhabdomyolysis.
Altered glycogen regulation/metabolism has additional effects on cellular function. Statin treatment has been associated with a modest risk for type 2 diabetes mellitus development. 38 Type 2 diabetes mellitus is marked by impaired insulin-stimulated glucose uptake, which reduces insulinstimulated muscle glycogen synthesis. Thus, statin-mediated defects in glycogen regulation may induce or further exacerbate diabetes mellitus symptoms. In addition, increased glucose metabolism is a hallmark of cancer. Reduction of glycogen metabolism genes could lead to decreased glucose metabolism and thus decreased cell proliferation. Indeed, decreased expression of hexokinase 2 and glucose-6-phosphate isomerase genes has been associated with reduced cell growth. [39] [40] [41] We observed that these genes are also downregulated by statin treatment, leading to reduced glucose metabolism and consequent reduced cell proliferation, consistent with anticancer effects reported with statin treatment.
Finally, we detected that the acetaldehyde dehydrogenase genes, ALDH1A1 and ALDH1B1, were downregulated by statin treatment. These enzymes are important in the ethanol degradation process whereby alcohol dehydrogenase oxidizes ethanol in the liver into acetaldehyde, which is then oxidized by acetaldehyde dehydrogenases into nontoxic acetic acid. However, the loss of acetaldehyde dehydrogenase activity will lead to accumulation of acetaldehyde and DNA damage. Acetaldehyde accumulation can induce alcoholic myopathy via its effect on decreasing protein synthesis, increasing proteolysis, and generating acetaldehyde protein adducts 42 and is an additional potential mechanism for statin-induced rhabdomyolysis. Interestingly, the aldehyde dehydrogenase ALDH3A1 expression is increased by statins and can inhibit cell proliferation in human corneal epithelial cells, 43 thus representing another mechanism for statin-mediated anticancer effects.
We describe here the development of a cynomoglus vascular surrogate system that mimics the baseline and inflammatory regional biology, as well as statin responsiveness, of the human vascular surrogate system. These systems enable mechanistic insight not achievable with in vivo studies. The overwhelming similarities between the cynomolgus and human vascular systems indicate that these platforms will provide significant translatability between nonhuman primate and human studies. Although we did not validate the translational statin response in the in vivo cynomolgus macaque because of time and cost constraints, we did perform a similar study where we validated the translation drug response of fenoldopam in rats with our rat vascular surrogate system and demonstrated similar responses. [44] [45] [46] Finally, we have found that certain biological pathways that may explain statin effects on other tissues, such as skeletal muscle, are conserved in our vascular tissue. Thus, many of the effects observed in the vascular system potentially may be translated to other organ systems.
